Arcus Biosciences, Inc. Revenue
Arcus Biosciences, Inc. (RCUS) reported Revenue of $41.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Revenue
us-gaap:Revenues · last filed 2026-08-05
- Arcus Biosciences, Inc. revenues for the quarter ending 2026-06-30 was $41.00M, a 74.38% decline year-over-year.
- Arcus Biosciences, Inc. revenues for the quarter ending 2026-03-31 was $17.00M, a 39.29% decline year-over-year.
- Arcus Biosciences, Inc. revenues for the quarter ending 2025-12-31 was $33.00M, a 26.92% increase year-over-year.
- Arcus Biosciences, Inc. revenues for the quarter ending 2025-09-30 was $26.00M, a 45.83% decline year-over-year.
- Arcus Biosciences, Inc. revenues for fiscal 2025 was $247.00M, a 4.26% decline from fiscal 2024.
- Arcus Biosciences, Inc. revenues for fiscal 2024 was $258.00M, a 120.51% increase from fiscal 2023.
- Arcus Biosciences, Inc. revenues for fiscal 2023 was $117.00M, a 4.46% increase from fiscal 2022.
- Arcus Biosciences, Inc. revenues for fiscal 2022 was $112.00M.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2026-06-30 | $41.00M 10-Q · filed 2026-08-05 | $58.00M 10-Q · filed 2026-08-05 | $91.00M derived: sum of 3 quarters · filed 2026-08-05 | $117.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $17.00M 10-Q · filed 2026-05-05 | $50.00M derived: sum of 2 quarters · filed 2026-05-05 | $76.00M derived: sum of 3 quarters · filed 2026-05-05 | $236.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $33.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $59.00M derived: sum of 2 quarters · filed 2026-02-25 | $219.00M derived: sum of 3 quarters · filed 2026-08-05 | $247.00M 10-K · filed 2026-02-25 |
| 2025-09-30 | $26.00M 10-Q · filed 2025-10-28 | $186.00M derived: sum of 2 quarters · filed 2026-08-05 | $214.00M 10-Q · filed 2025-10-28 | $240.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $160.00M 10-Q · filed 2026-08-05 | $188.00M 10-Q · filed 2026-08-05 | $214.00M derived: sum of 3 quarters · filed 2026-08-05 | $262.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $28.00M 10-Q · filed 2026-05-05 | $54.00M derived: sum of 2 quarters · filed 2026-05-05 | $102.00M derived: sum of 3 quarters · filed 2026-05-05 | $141.00M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $26.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $74.00M derived: sum of 2 quarters · filed 2026-02-25 | $113.00M derived: sum of 3 quarters · filed 2026-02-25 | $258.00M 10-K · filed 2026-02-25 |
| 2024-09-30 | $48.00M 10-Q · filed 2025-10-28 | $87.00M derived: sum of 2 quarters · filed 2025-10-28 | $232.00M 10-Q · filed 2025-10-28 | |
| 2024-06-30 | $39.00M 10-Q · filed 2025-08-06 | $184.00M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $145.00M 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $117.00M 10-K · filed 2026-02-25 | |||
| 2022-12-31 | $112.00M 10-K · filed 2025-02-25 | |||
| 2020-12-31 | $9.49M 10-K · filed 2021-02-25 | $74.02M derived: sum of 2 quarters · filed 2021-02-25 | $75.77M derived: sum of 3 quarters · filed 2021-02-25 | $77.52M derived: sum of 4 quarters · filed 2021-02-25 |
| 2020-09-30 | $64.53M 10-K · filed 2021-02-25 | $66.28M derived: sum of 2 quarters · filed 2021-02-25 | $68.03M derived: sum of 3 quarters · filed 2021-02-25 | $77.78M derived: sum of 4 quarters · filed 2021-02-25 |
| 2020-06-30 | $1.75M 10-K · filed 2021-02-25 | $3.50M derived: sum of 2 quarters · filed 2021-02-25 | $13.25M derived: sum of 3 quarters · filed 2021-02-25 | $15.00M derived: sum of 4 quarters · filed 2021-02-25 |
| 2020-03-31 | $1.75M 10-K · filed 2021-02-25 | $11.50M derived: sum of 2 quarters · filed 2021-02-25 | $13.25M derived: sum of 3 quarters · filed 2021-02-25 | $15.00M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-12-31 | $9.75M 10-K · filed 2021-02-25 | $11.50M derived: sum of 2 quarters · filed 2021-02-25 | $13.25M derived: sum of 3 quarters · filed 2021-02-25 | $15.00M 10-K · filed 2020-03-05 |
| 2019-09-30 | $1.75M 10-K · filed 2021-02-25 | $3.50M derived: sum of 2 quarters · filed 2021-02-25 | $5.25M 10-Q · filed 2019-11-05 | $6.81M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $1.75M 10-K · filed 2021-02-25 | $3.50M 10-Q · filed 2019-08-06 | $5.06M derived: sum of 3 quarters · filed 2021-02-25 | $9.35M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $1.75M 10-K · filed 2021-02-25 | $3.31M derived: sum of 2 quarters · filed 2021-02-25 | $7.60M derived: sum of 3 quarters · filed 2021-02-25 | $8.85M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $1.56M 10-K · filed 2020-03-05 | $5.85M derived: sum of 2 quarters · filed 2020-03-05 | $7.10M derived: sum of 3 quarters · filed 2020-03-05 | $8.35M 10-K · filed 2020-03-05 |
| 2018-09-30 | $4.29M 10-K · filed 2020-03-05 | $5.54M derived: sum of 2 quarters · filed 2020-03-05 | $6.79M 10-Q · filed 2019-11-05 | $8.04M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-06-30 | $1.25M 10-K · filed 2020-03-05 | $2.50M 10-Q · filed 2019-08-06 | $3.75M derived: sum of 3 quarters · filed 2020-03-05 | $3.91M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-03-31 | $1.25M 10-K · filed 2020-03-05 | $2.50M derived: sum of 2 quarters · filed 2020-03-05 | $2.66M derived: sum of 3 quarters · filed 2020-03-05 | |
| 2017-12-31 | $1.25M 10-K · filed 2019-03-05 | $1.41M derived: sum of 2 quarters · filed 2019-03-05 | $1.41M 10-K · filed 2019-03-05 | |
| 2017-09-30 | $163.00K 10-K · filed 2019-03-05 | $163.00K 10-Q · filed 2018-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |